Patents by Inventor Ilango Subramanian

Ilango Subramanian has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220183968
    Abstract: Provided here are new ophthalmologically suitable pharmaceutical compositions comprising an effective amount of a moxifloxacin compound and an effective amount of a triamcinolone compound and a suspension component comprising a polysorbate, hyaluronic acid, or both. In aspects, the compositions are stable suspensions maintaining physical stability and chemical stability for extended periods of time (e.g., exhibiting no sustained flocculation, coagulation, or clumping after several months of storage under typical storage conditions). In aspects, the compositions comprise a non-ionic surfactant or, e.g., a non-ionic suspension agent providing both surfactant and suspension functionality. In aspects, such compositions further comprise an effective amount of a chelating agent/component. Further described are related compositions and methods of making and using such compositions, e.g., in the treatment of eye infections.
    Type: Application
    Filed: March 3, 2022
    Publication date: June 16, 2022
    Inventors: Mandar V. Shah, Ilango Subramanian, Veerappan Subramanian, Aman Trehan
  • Patent number: 11344566
    Abstract: Disclosed herein are compositions comprising tobramycin or a tobramycin derivative that exhibit improvements in permeation of corneal cells, retention in corneal cells, or both. Such compositions can comprise tobramycin or tobramycin derivative(s) complexed to an agent which facilitates improved permeation of corneal cells, retention in corneal cells, or both. The invention also relates to a process of preparing such compositions.
    Type: Grant
    Filed: May 22, 2021
    Date of Patent: May 31, 2022
    Assignee: Somerset Therapeutics, LLC
    Inventors: Mandar V Shah, Veerappan Subramanian, Ilango Subramanian
  • Publication number: 20220133845
    Abstract: The invention relates to formulations and compositions comprising one or more glycopeptide antibodies or a pharmaceutically acceptable salt thereof for parenteral administration. In particular, stable liquid formulations and compositions comprising vancomycin or a pharmaceutically acceptable salt thereof, N-acetyl-methionine and one or more pharmaceutically acceptable excipients. The invention also relates to a process of preparing such compositions and methods and uses thereof.
    Type: Application
    Filed: October 27, 2021
    Publication date: May 5, 2022
    Applicant: SOMERSET THERAPEUTICS, LLC
    Inventors: Mandar V. SHAH, Ilango SUBRAMANIAN, Veerappan SUBRAMANIAN
  • Publication number: 20220133844
    Abstract: The invention relates to formulations and compositions comprising one or more glycopeptide antibodies or a pharmaceutically acceptable salt thereof for parenteral administration. In particular, stable liquid formulations and compositions comprising vancomycin or a pharmaceutically acceptable salt thereof, N-acetyl-methionine and one or more pharmaceutically acceptable excipients. The invention also relates to a process of preparing such compositions and methods and uses thereof.
    Type: Application
    Filed: October 27, 2021
    Publication date: May 5, 2022
    Applicant: SOMERSET THERAPEUTICS, LLC
    Inventors: Mandar V. SHAH, Ilango SUBRAMANIAN, Veerappan SUBRAMANIAN
  • Patent number: 11298315
    Abstract: Provided here are new ophthalmologically suitable pharmaceutical compositions comprising an effective amount of a moxifloxacin compound and an effective amount of a triamcinolone compound. In aspects, the compositions are stable suspensions, which maintain physical stability and chemical stability for extended periods of time (e.g., exhibiting no sustained flocculation, coagulation, or clumping after several months of storage under typical storage conditions). In aspects, the compositions are suspensions that include a suspension component comprising one or more suspension agents. In aspects, the suspension component includes an ionic suspension agent. In aspects, the composition also or alternatively comprises a non-ionic surfactant, non-ionic suspension agent, or both, or an agent that provides both functions. In aspects, such compositions further comprise an effective amount of a chelating agent/component. Further described are related compositions and methods of making and using such compositions, e.g.
    Type: Grant
    Filed: August 26, 2021
    Date of Patent: April 12, 2022
    Assignee: SOMERSET THERAPEUTICS, LLC.
    Inventors: Mandar V. Shah, Ilango Subramanian, Veerappan Subramanian, Aman Trehan
  • Patent number: 11298368
    Abstract: Disclosed herein are compositions comprising tobramycin or a tobramycin derivative that exhibit improvements in permeation of corneal cells, retention in corneal cells, or both. Such compositions can comprise tobramycin or tobramycin derivative(s) complexed to an agent which facilitates improved permeation of corneal cells, retention in corneal cells, or both. The invention also relates to a process of preparing such compositions.
    Type: Grant
    Filed: November 1, 2021
    Date of Patent: April 12, 2022
    Assignee: SOMERSET THERAPEUTICS, LLC.
    Inventors: Mandar V. Shah, Veerappan Subramanian, Ilango Subramanian
  • Publication number: 20220105101
    Abstract: Disclosed herein are pharmacologically acceptable and ophthalmologically suitable compositions and methods of their use in treating ophthalmic diseases or related conditions. In aspects, the invention provides compositions comprising effective amounts of carbonic anhydrase inhibitor(s) and alpha-2-adrenergic agonist(s). In facets, compositions comprise a penetration enhancer component comprising one or more penetration enhancer compound(s)/molecule(s). In aspects, the invention provides compositions comprising effective amounts of brimonidine compound(s) and brinzolamide compound(s) capable of being administered once or twice daily for the treatment of elevated intraocular pressure, but which provide similar efficacy to a similar or substantially identical reference product requiring administration three times per day.
    Type: Application
    Filed: October 5, 2021
    Publication date: April 7, 2022
    Inventors: Mandar V. Shah, Ilango Subramanian, Veerappan Subramanian, Aman Trehan
  • Publication number: 20220105100
    Abstract: Disclosed herein are safe pharmacologically acceptable and ophthalmologically suitable compositions and methods of their use in treating ophthalmic diseases or related conditions. Disclosed are compositions comprising effective amounts of carbonic anhydrase inhibitor(s) and alpha-2-adrenergic agonist(s) and an effective amount of a penetration enhancement component comprising one or more penetration enhancer compound(s)/molecule(s), e.g., benzalkonium chloride, which detectably or significantly increases the penetration of API(s) of the composition. In aspects, the invention provides compositions comprising a brinzolamide compound in an amount of about 0.1 wt. %-10 wt. % of the composition, a brimonidine compound, e.g., brimonidine tartrate, in an amount of about 0.01 wt. %-0.5 wt. % of the composition, one or more borate-polyol complexes in an amount of about 0.5 wt. %-6 wt. % of the composition, and a penetration enhancement component comprising benzalkonium chloride, in, for example, an amount of about 0.
    Type: Application
    Filed: October 5, 2021
    Publication date: April 7, 2022
    Inventors: Mandar V. Shah, Ilango Subramanian, Veerappan Subramanian, Aman Trehan
  • Publication number: 20220105103
    Abstract: Disclosed herein are safe pharmacologically acceptable and ophthalmologically suitable compositions and methods of their use in treating ophthalmic diseases or related conditions. Disclosed are compositions comprising effective amounts of carbonic anhydrase inhibitor(s) and alpha-2-adrenergic agonist(s) and an effective amount of a penetration enhancement component comprising one or more penetration enhancer compound(s)/molecule(s), e.g., benzalkonium chloride, which detectably or significantly increases the penetration of API(s) of the composition. In aspects, the invention provides compositions comprising a brinzolamide compound in an amount of about 0.1 wt. %-10 wt. % of the composition, a brimonidine compound, e.g., brimonidine tartrate, in an amount of about 0.01 wt. %-0.5 wt. % of the composition, one or more borate-polyol complexes in an amount of about 0.5 wt. %-6 wt. % of the composition, and a penetration enhancement component comprising benzalkonium chloride, in, for example, an amount of about 0.
    Type: Application
    Filed: October 5, 2021
    Publication date: April 7, 2022
    Inventors: Mandar V. Shah, Ilango Subramanian, Veerappan Subramanian, Aman Trehan
  • Publication number: 20220105102
    Abstract: Disclosed herein are pharmacologically acceptable and ophthalmologically suitable compositions and methods of their use in treating ophthalmic diseases or related conditions. In aspects, the invention provides compositions comprising effective amounts of carbonic anhydrase inhibitor(s) and alpha-2-adrenergic agonist(s). In facets, compositions comprise a penetration enhancer component comprising one or more penetration enhancer compound(s)/molecule(s). In aspects, the invention provides compositions comprising effective amounts of brimonidine compound(s) and brinzolamide compound(s) capable of being administered once or twice daily for the treatment of elevated intraocular pressure, but which provide similar efficacy to a similar or substantially identical reference product requiring administration three times per day.
    Type: Application
    Filed: October 5, 2021
    Publication date: April 7, 2022
    Inventors: Mandar V. Shah, Ilango Subramanian, Veerappan Subramanian, Aman Trehan
  • Publication number: 20220062301
    Abstract: Provided here are new ophthalmologically suitable pharmaceutical compositions comprising an effective amount of moxifloxacin, prednisolone, and bromfenac. In aspects, the compositions are suspensions that include a suspension component comprising one or more suspension agents. In aspects, the suspension component includes an ionic suspension agent. In aspects, the composition also or alternatively comprises a non-ionic surfactant, non-ionic suspension agent, or both, or an agent that provides both functions. In aspects, such compositions further comprise an effective amount of a chelating agent/component. Further described are related compositions and methods of making and using such compositions, e.g., in the treatment of eye infections.
    Type: Application
    Filed: August 26, 2021
    Publication date: March 3, 2022
    Inventors: Mandar V. Shah, Ilango Subramanian, Veerappan Subramanian, Aman Trehan
  • Publication number: 20220062271
    Abstract: Provided here are new optahalmologically suitable pharmaceutical compositions comprising an effective amount of a moxifloxacin compound and an effective amount of a loteprednol compound. In aspects, the compositions are stable suspensions, which maintain physical stability and chemical stability for extended periods of time (e.g., exhibiting no sustained flocculation, coagulation, or clumping after several months of storage under typical storage conditions). In aspects, the compositions are suspensions that include a suspension component comprising one or more suspension agents. In aspects, the suspension component includes an ionic suspension agent. In aspects, the composition also or alternatively comprises a non-ionic surfactant, non-ionic suspension agent, or both, or an agent that provides both functions. In aspects, such compositions further comprise an effective amount of a chelating agent/component. Further described are related compositions and methods of making and using such compositions, e,g.
    Type: Application
    Filed: August 26, 2021
    Publication date: March 3, 2022
    Inventors: Mandar V. Shah, Ilango Subramanian, Veerappan Subramanian, Aman Trehan
  • Publication number: 20220062303
    Abstract: Provided here are new ophthalmologically suitable pharmaceutical compositions comprising an effective amount of a moxifloxacin compound and an effective amount of a prednisolone compound. In aspects, the compositions are stable suspensions, which maintain physical stability and chemical stability for extended periods of time (e.g., exhibiting no sustained flocculation, coagulation, or clumping after several months of storage under typical storage conditions). In aspects, the compositions are suspensions that include a suspension component comprising one or more suspension agents. In aspects, the suspension component includes an ionic suspension agent. In aspects, the composition also or alternatively comprises a non-ionic surfactant, non-ionic suspension agent, or both, or an agent that provides both functions. In aspects, such compositions further comprise an effective amount of a chelating agent/component. Further described are related compositions and methods of making and using such compositions, e.g.
    Type: Application
    Filed: August 26, 2021
    Publication date: March 3, 2022
    Inventors: Mandar V. Shah, Ilango Subramanian, Veerappan Subramanian, Aman Trehan
  • Publication number: 20220062168
    Abstract: Provided here are new ophthalmological methods for the treatment or prophylaxis of ocular bacterial infections and related conditions comprising delivering an effective amount of an ophthalmologically suitable composition comprising an effective amount of a moxifloxacin compound and an effective amount of a triamcinolone compound. In aspects, methods comprise delivery of the composition by injection. In aspects, the delivered compositions are stable suspensions, which maintain physical stability and chemical stability for extended periods of time (e.g., exhibiting no sustained flocculation, coagulation, or clumping after several months of storage under typical storage conditions). In aspects, compositions are suspensions that include a suspension component comprising one or more suspension agents. In aspects, the suspension component includes an ionic suspension and may also or alternatively comprises a non-ionic surfactant, non-ionic suspension agent, or both, or, an agent that provides both functions.
    Type: Application
    Filed: August 26, 2021
    Publication date: March 3, 2022
    Inventors: Mandar V. Shah, Ilango Subramanian, Veerappan Subramanian, Aman Trehan
  • Publication number: 20220062302
    Abstract: Provided here are new ophthalmologically suitable pharmaceutical compositions comprising an effective amount of gatifloxacin, prednisolone, and bromfenac. In aspects, the compositions are suspensions that include a suspension component comprising one or more suspension agents. In aspects, the suspension component includes an ionic suspension agent. In aspects, the composition also or alternatively comprises a non-ionic surfactant, non-ionic suspension agent, or both, or an agent that provides both functions. In aspects, such compositions further comprise an effective amount of a chelating agent/component. Further described are related compositions and methods of making and using such compositions, e.g., in the treatment of eye infections.
    Type: Application
    Filed: August 26, 2021
    Publication date: March 3, 2022
    Inventors: Mandar V. Shah, Ilango Subramanian, Veerappan Subramanian, Aman Trehan
  • Publication number: 20220062167
    Abstract: Provided here are new ophthalmologically suitable pharmaceutical compositions comprising an effective amount of a moxifloxacin compound and an effective amount of a triamcinolone compound. In aspects, the compositions are stable suspensions, which maintain physical stability and chemical stability for extended periods of time (e.g., exhibiting no sustained flocculation, coagulation, or clumping after several months of storage under typical storage conditions). In aspects, the compositions are suspensions that include a suspension component comprising one or more suspension agents. In aspects, the suspension component includes an ionic suspension agent. In aspects, the composition also or alternatively comprises a non-ionic surfactant, non-ionic suspension agent, or both, or an agent that provides both functions. In aspects, such compositions further comprise an effective amount of a chelating agent/component. Further described are related compositions and methods of making and using such compositions, e.g.
    Type: Application
    Filed: August 26, 2021
    Publication date: March 3, 2022
    Inventors: Mandar V. Shah, Ilango Subramanian, Veerappan Subramanian, Aman Trehan
  • Publication number: 20220054519
    Abstract: Disclosed herein are compositions comprising tobramycin or a tobramycin derivative that exhibit improvements in permeation of corneal cells, retention in corneal cells, or both. Such compositions can comprise tobramycin or tobramycin derivative(s) complexed to an agent which facilitates improved permeation of corneal cells, retention in corneal cells, or both. The invention also relates to a process of preparing such compositions.
    Type: Application
    Filed: November 1, 2021
    Publication date: February 24, 2022
    Inventors: Mandar V. Shah, Veerappan Subramanian, Ilango Subramanian
  • Publication number: 20220054518
    Abstract: Disclosed herein are compositions comprising tobramycin or a tobramycin derivative that exhibit improvements in permeation of corneal cells, retention in corneal cells, or both. Such compositions can comprise tobramycin or tobramycin derivative(s) complexed to an agent which facilitates improved permeation of corneal cells, retention in corneal cells, or both. The invention also relates to a process of preparing such compositions.
    Type: Application
    Filed: November 1, 2021
    Publication date: February 24, 2022
    Inventors: Mandar V. Shah, Veerappan Subramanian, Ilango Subramanian
  • Publication number: 20220054517
    Abstract: Disclosed herein are compositions comprising tobramycin or a tobramycin derivative that exhibit improvements in permeation of corneal cells, retention in corneal cells, or both. Such compositions can comprise tobramycin or tobramycin derivative(s) complexed to an agent which facilitates improved permeation of corneal cells, retention in corneal cells, or both. The invention also relates to a process of preparing such compositions.
    Type: Application
    Filed: November 1, 2021
    Publication date: February 24, 2022
    Inventors: Mandar V. Shah, Veerappan Subramanian, Ilango Subramanian
  • Publication number: 20220016054
    Abstract: The present invention relates to liquid formulations of epinephrine or a pharmaceutically acceptable salt thereof intended for parenteral administration. In particular, the invention provides liquid formulations comprising levorotatory-epinephrine (l-epinephrine) in a concentration of about 0.5 to about 1.5 mg/mL and at least one antioxidant. The antioxidant is selected from the group consisting of ascorbic acid, sodium ascorbate, monothioglycerol, vitamin-A, vitamin-B1, vitamin-B2, vitamin-B6, vitamin-E, butylated hydroxy toluene, butylated hydroxy anisole and propyl gallate, alone or in a combination. The formulations prepared by using the current invention exhibit good physical and chemical stability.
    Type: Application
    Filed: July 16, 2021
    Publication date: January 20, 2022
    Applicant: Somerset Therapeutics LLC
    Inventors: Mandar V. Shah, Santhosh Kamath, Sathiyamoorthi Natarajan, Ilango Subramanian, Veerappan Subramanian